MedTrace Logo

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-05-12

No results posted yet for this study

Summary

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Conditions

Interventions

DRUG

Volrustomig

Participants will receive volrustomig via intravenous (IV) infusion.

DRUG

Carboplatin

Participants will receive carboplatin via IV infusion.

DRUG

Pemetrexed

Participants will receive pemetrexed via IV infusion.

DRUG

Ramucirumab

Participants will receive ramucirumab via IV infusion.

DRUG

Paclitaxel

Participants will receive paclitaxel via IV infusion.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-27
Primary Completion
2027-07-30
Completion
2027-07-30
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • France
  • Georgia
  • Greece
  • Italy
  • Malaysia
  • Portugal
  • Romania
  • Serbia
  • South Korea
  • Spain
  • Switzerland
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06448754 on ClinicalTrials.gov